Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision an...
Surrozen, Inc. (SRZN)
Company Research
Source: Yahoo! Finance
Surrozen's antibody based Wnt mimetic also increased detectable tear volume production in dry eye disease models SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that preclinical data highlighting the potential for Surrozen's antibody-based Wnt mimetic technologies to treat cornea endothelial damage and Dry Eye Disease (DED) were presented on May 7, 2024 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle. “We are pleased to present new data based on preclinical studies that demonstrate activation of the Wnt pathway leads to regeneration of cells in damaged eye tear gland tissue in Dry Eye Disease and proliferation of endothelial cells in Fuchs' Endothelial Cell Dystrophy, that can halt the loss of vision and blindness that develop
Show less
Read more
Impact Snapshot
Event Time:
SRZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRZN alerts
High impacting Surrozen, Inc. news events
Weekly update
A roundup of the hottest topics
SRZN
News
- Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual MeetingGlobeNewswire
- Surrozen Provides First Quarter 2024 Financial Results and Business Update [Yahoo! Finance]Yahoo! Finance
- Surrozen Provides First Quarter 2024 Financial Results and Business UpdateGlobeNewswire
- Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis [Yahoo! Finance]Yahoo! Finance
- Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary FibrosisGlobeNewswire
SRZN
Earnings
- 5/8/24 - Beat
SRZN
Sec Filings
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 5/2/24 - Form 4
- SRZN's page on the SEC website